Promising Cell-Free Therapeutic Approach for Pancreatic Cancer

Strategic Insights -

Researchers at the Slovak Academy of Sciences have made significant progress in developing a novel cell-free gene-directed enzyme prodrug therapy for pancreatic ductal adenocarcinoma (PDAC). This innovative approach leverages conditioned medium from placenta-derived mesenchymal stem cells engineered to express the yeast cytosine deaminase::uracil phosphoribosyltransferase (yCD::UPRT) fusion enzyme.

The study, published in the journal Biomedicine & Pharmacotherapy, presents a preclinical investigation of the therapeutic efficacy of this approach in coculture models comprising PDAC cell lines, patient-derived xenograft organoids, and cancer-associated fibroblasts. The research demonstrated that the treatment enabled efficient enzymatic conversion of 5-fluorocytosine to 5-fluorouracil, resulting in robust, dose-dependent cytotoxicity across monocultures and stromal-rich cocultures.

Key Takeaways:

  • The extreme lethality and limited treatment options for pancreatic ductal adenocarcinoma underscore the urgent need for innovative therapeutic strategies.
  • The research presents a preclinical investigation of a cell-free gene-directed enzyme prodrug therapy based on conditioned medium from placenta-derived mesenchymal stem cells engineered to express the yCD::UPRT fusion enzyme.
  • The treatment enabled efficient enzymatic conversion of 5-fluorocytosine to 5-fluorouracil, resulting in robust, dose-dependent cytotoxicity across monocultures and stromal-rich cocultures.
  • The therapeutic response was governed primarily by tumor cell characteristics rather than cancer-associated fibroblast heterogeneity.
  • The research demonstrated the potential of this approach to overcome cancer-associated fibroblast-mediated drug resistance.
  • The treatment showed promising results in patient-derived xenograft organoids, with 100 L of condition medium inducing cytotoxicity comparable to 1 mg/mL of 5-FU.

Statistics:

  • 50% to 80% reduction in viability was observed in PDAC cell lines and coculture models treated with yCD::UPRT-PlacMSC-cCM in the presence of 5-fluorocytosine.
  • 10 mg/mL of 5-fluorouracil was produced from an initial 100 mg/mL of 5-fluorocytosine upon treatment with yCD::UPRT-PlacMSC-cCM.
  • The study used coculture models comprising PDAC cell lines (BxPC-3, MIA PaCa-2, SU.86.86), patient-derived xenograft organoids, and cancer-associated fibroblasts.

Sources:

  • Placental mesenchymal stem cells: A promising platform for advancing gene therapy in pancreatic ductal adenocarcinoma. Biomedicine & Pharmacotherapy, 2025;190:118428.
  • NewsRx. Investigators at Slovak Academy of Sciences Release New Data on Cancer Gene Therapy (Placental mesenchymal stem cells: A promising platform for advancing gene therapy in pancreatic ductal adenocarcinoma). Biotech Week. August 27, 2025; p 28.